Curcumin for Premenstrual Syndrome

Verdict: Published

Across 6 PubMed studies, the evidence for Curcumin in Premenstrual Syndrome grades Tier C — weak evidence.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.50

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Published

Confidence

80%

Highly consistent evidence

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.50

L5 Clinical bodiesAuthoritative stance

0.62

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.502
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Curcumin, a bioactive supplement for premenstrual syndrome and dysmenorrhea: A systematic review of randomised clinical trials

PMID: 41281701 2025 系統性回顧 n = 850

Finding: Narrative SR of 10 RCTs (~850 women): 6 of 10 trials reported a significant reduction in PMS and dysmenorrhea symptoms, but no pooled effect size was computed and the authors stress optimal dose/duration remain undefined.

Academic

View on PubMed

Effect of Curcumin on Dysmenorrhea and Symptoms of Premenstrual Syndrome: A Systematic Review and Meta-Analysis (RETRACTED 2025)

PMID: 38266637 2024 統合分析 n = 379

Finding: RETRACTED (Korean J Fam Med 2025, retraction notice PMID 40139927): originally reported PMS overall score SMD -1.41 (95% CI -1.81 to -1.02; 2 studies, I2=0%) and dysmenorrhea MD -1.25 (95% CI -1.52 to -0.98; 3 studies, I2=31%), but the retraction nullifies this as usable evidence.

🟠 Limited quality Effect size: PMS SMD -1.41 (95% CI -1.81 to -1.02); dysmenorrhea MD -1.25 (95% CI -1.52 to -0.98) — ARTICLE RETRACTED 2025

View on PubMed

Curcumin attenuates severity of premenstrual syndrome symptoms: A randomized, double-blind, placebo-controlled trial

PMID: 26051565 2015 RCT (double-blind) n = 70

Finding: Curcumin (~100 mg curcuminoid/day, 7 days pre- to 3 days post-menses x3 cycles) reduced total PMS severity from 102.06+/-39.64 to 42.47+/-16.37 vs placebo 106.06 to 91.60, a significant between-group mean difference (~45 points, p<0.001).

Academic Effect size: Between-group MD ~45 PMS-severity points; curcumin within-group change 59.59 (95% CI 46.19–72.99) vs placebo 14.45 (95% CI 2.69–26.22), p<0.001

View on PubMed

Effects of curcumin on menstrual pattern, premenstrual syndrome, and dysmenorrhea: A triple-blind, placebo-controlled clinical trial

PMID: 34708460 2021 RCT (double-blind) n = 124

Finding: With 500 mg curcuminoid/day, PMS (PSST) fell similarly in both arms (curcumin 32.5->21.6 vs placebo 31.7->23.4) and dysmenorrhea improved 64% vs 53.3%; authors concluded curcumin had effects COMPARABLE to placebo (no significant between-group benefit on the primary endpoint).

Academic Effect size: No significant between-group difference; PSST curcumin 32.5→21.6 vs placebo 31.7→23.4 (curcumin comparable to placebo)

View on PubMed

The effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial

PMID: 40671058 2025 RCT (double-blind) n = 62

Finding: Phospholipid curcumin 500 mg/day cut PSST in cycle 2 (MD -5.2, 95% CI -9.6 to -0.9, p=0.018) but lost significance by cycle 3 (MD -5.0, 95% CI -10.3 to 0.2, p=0.064); dysmenorrhea VAS was significantly lower in both cycles (cycle 2 MD -0.8, p=0.012; cycle 3 MD -0.8, p=0.029).

Academic Effect size: PSST cycle 2 MD -5.2 (95% CI -9.6 to -0.9, p=0.018); cycle 3 MD -5.0 (95% CI -10.3 to 0.2, p=0.064, NS); dysmenorrhea VAS MD -0.8 both cycles (p=0.012, p=0.029)

View on PubMed

Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhea: A randomized controlled trial

PMID: 37394650 2023 RCT (double-blind) n = 76

Finding: 500 mg curcuminoid+piperine/day significantly lowered median hs-CRP (0.30 to 0.20 mg/L, p=0.041) but left WBC, neutrophils, NLR, PLR and all iron-metabolism markers unchanged (p>0.05); a surrogate-marker result, not a clinical PMS-severity endpoint.

🟠 Limited quality Academic Effect size: hs-CRP median 0.30 (0.0–1.10) → 0.20 (0.0–1.3) mg/L, p=0.041; iron profile and other inflammatory markers unchanged (p>0.05)

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA

Cautious

the Panel established an ADI for curcumin of 3 mg/kg bw/day source↗

L4c UK NHS

Cautious

Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. source↗

L4d TW TFDA / 衛福部

Cautious

薑黃素每人每日攝取量為每公斤體重0~3毫克，每日不超過200毫克為宜 source↗

L4e WHO

Neutral

Rhizoma Curcumae Longae source↗

L5a NIH Office of Dietary Supplements

Cautious

We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. source↗

L5c Cleveland Clinic

Supportive

Curcumin is especially effective in easing mood swings and cramps. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬6 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-pms-INT-curcumin-001 繁體中文版 →